KTTA Stock Overview
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Pasithea Therapeutics Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.25 |
52 Week High | US$17.40 |
52 Week Low | US$5.25 |
Beta | 0.90 |
1 Month Change | -0.68% |
3 Month Change | -2.02% |
1 Year Change | -3.33% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -89.82% |
Recent News & Updates
Shareholder Returns
KTTA | US Biotechs | US Market | |
---|---|---|---|
7D | 1.1% | 0.9% | 0.2% |
1Y | -3.3% | 11.0% | 28.1% |
Return vs Industry: KTTA underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: KTTA underperformed the US Market which returned 28.8% over the past year.
Price Volatility
KTTA volatility | |
---|---|
KTTA Average Weekly Movement | 10.9% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KTTA has not had significant price volatility in the past 3 months.
Volatility Over Time: KTTA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 15 | Tiago Marques | https://www.pasithea.com |
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers.
Pasithea Therapeutics Corp. Fundamentals Summary
KTTA fundamental statistics | |
---|---|
Market cap | US$7.45m |
Earnings (TTM) | -US$16.74m |
Revenue (TTM) | US$486.56k |
15.5x
P/S Ratio-0.5x
P/E RatioIs KTTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KTTA income statement (TTM) | |
---|---|
Revenue | US$486.56k |
Cost of Revenue | US$113.20k |
Gross Profit | US$373.36k |
Other Expenses | US$17.11m |
Earnings | -US$16.74m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -16.07 |
Gross Margin | 76.74% |
Net Profit Margin | -3,440.17% |
Debt/Equity Ratio | 0% |
How did KTTA perform over the long term?
See historical performance and comparison